Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

B. Saltz, Leonard; J. Meropol, Neal; J. Loehrer, Patrick; N. Needle, Michael; Kopit, Justin; J. Mayer, Robert

doi:10.1200/jco.2004.10.182

Public

Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

Published in Journal of Clinical Oncology • Mar 2, 2004

Authors:

Leonard B. Saltz

Neal J. Meropol

Patrick J. Loehrer

Abstract

PURPOSE: To evaluate the antitumor activity and toxicity of single-agent cetuximab in patients with chemotherapy-refractory colorectal cancer whose tumors express the epidermal growth factor receptor. PATIENTS AND METHODS: Phase II, open-label clinical trial. Patients were required to have EGFr expr...

Subject

Medicine

Cetuximab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!